# Mardi C. Dier

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/mardi-c-dier
Canonical HTML page: https://gethealthbrief.com/entity/mardi-c-dier

## Timeline

- **2026-01-01**: Payer Agreement Shift — New payer contracts take effect, shifting GTN expectations to the high 30% range for the fiscal year.
- **2025-12-31**: Q4 Milestone — Patient count surpasses 36,000 and quarterly revenue exceeds $320 million.
- **2025-09-30**: GLP-1 Strategic Acquisition — Madrigal makes a $120 million upfront payment for an oral GLP-1 asset to expand its metabolic pipeline.
- **2025-01-01**: Rezdiffra Full-Year Launch — Madrigal begins its first full year of commercial sales for the first-ever approved MASH treatment.

## Recent coverage (1 stories)

### Madrigal Pharmaceuticals Triples Q4 Revenue as Rezdiffra Adoption Accelerates
2026-02-24 00:09:59 · Sentiment: Positive · Impact: 7/10 · Sources: 5

Madrigal Pharmaceuticals reported a transformative Q4 2025, with Rezdiffra net sales reaching $321.1 million and a patient base exceeding 36,000. The company is aggressively expanding its metabolic pipeline, integrating GLP-1 and siRNA technologies to solidify its leadership in the MASH market.
Full story: https://gethealthbrief.com/story/madrigal-q4-2025-earnings-rezdiffra-mash-market

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.